Stock 601607 SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Pharmaceuticals Holding Co., Ltd

Equities

601607

CNE000000C82

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
17.92 CNY -0.78% Intraday chart for Shanghai Pharmaceuticals Holding Co., Ltd +0.67% +7.11%
Apr. 29 Shanghai Pharmaceuticals Holding's Q1 Profit Rises 2% as Revenue Grows 6% MT
Apr. 26 Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 47,781 47,493 49,277 60,072 56,107 59,426 - -
Enterprise Value (EV) 1 63,090 55,488 57,141 69,931 69,900 72,693 78,839 69,518
P/E ratio 12.8 x 12.2 x 11.1 x 11.1 x 16.4 x 12.9 x 11.1 x 9.57 x
Yield 2.4% 2.5% 2.11% 3.42% 2.45% 3.34% 3.76% 4.09%
Capitalization / Revenue 0.26 x 0.25 x 0.23 x 0.26 x 0.22 x 0.21 x 0.19 x 0.17 x
EV / Revenue 0.34 x 0.29 x 0.26 x 0.3 x 0.27 x 0.25 x 0.25 x 0.2 x
EV / EBITDA 8.22 x 5.85 x 5.53 x 6.24 x 7.47 x 6.63 x 6.04 x 4.86 x
EV / FCF 19.3 x 13.2 x 60.6 x 31.5 x 28.6 x 37.8 x 121 x 20.2 x
FCF Yield 5.18% 7.6% 1.65% 3.17% 3.49% 2.65% 0.82% 4.95%
Price to Book 1.25 x 1.2 x 1.14 x 0.98 x 0.9 x 0.92 x 0.87 x 0.81 x
Nbr of stocks (in thousands) 2,842,089 2,842,089 2,842,089 3,696,414 3,703,301 3,703,301 - -
Reference price 2 18.37 19.20 19.87 17.83 16.73 17.92 17.92 17.92
Announcement Date 3/27/20 3/26/21 3/29/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 186,566 191,909 215,824 231,981 260,295 287,841 316,963 348,148
EBITDA 1 7,672 9,483 10,324 11,216 9,360 10,961 13,047 14,312
EBIT 1 6,214 7,184 8,205 9,015 7,667 9,326 11,498 12,811
Operating Margin 3.33% 3.74% 3.8% 3.89% 2.95% 3.24% 3.63% 3.68%
Earnings before Tax (EBT) 1 6,262 7,175 8,144 8,808 7,054 8,848 10,029 11,249
Net income 1 4,081 4,496 5,093 5,617 3,768 5,077 5,840 6,448
Net margin 2.19% 2.34% 2.36% 2.42% 1.45% 1.76% 1.84% 1.85%
EPS 2 1.440 1.580 1.790 1.610 1.020 1.388 1.620 1.872
Free Cash Flow 1 3,269 4,219 942.6 2,219 2,440 1,925 650.1 3,442
FCF margin 1.75% 2.2% 0.44% 0.96% 0.94% 0.67% 0.21% 0.99%
FCF Conversion (EBITDA) 42.61% 44.49% 9.13% 19.78% 26.07% 17.57% 4.98% 24.05%
FCF Conversion (Net income) 80.11% 93.83% 18.51% 39.5% 64.76% 37.92% 11.13% 53.38%
Dividend per Share 2 0.4400 0.4800 0.4200 0.6100 0.4100 0.5977 0.6735 0.7329
Announcement Date 3/27/20 3/26/21 3/29/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 54,852 - 54,809 62,904 57,369 66,226 66,366 64,916 62,787 70,153 72,069 75,528 74,375 63,666 73,215
EBITDA 1 - - - - - - - - - - 8,320 -7,752 -534.3 2,498 2,805
EBIT 1 1,404 - 3,804 1,822 1,393 2,666 1,893 1,998 1,489 2,415 7,894 -8,177 -960.1 2,046 2,353
Operating Margin 2.56% - 6.94% 2.9% 2.43% 4.02% 2.85% 3.08% 2.37% 3.44% 10.95% -10.83% -1.29% 3.21% 3.21%
Earnings before Tax (EBT) 1 - - - - - - - - - 2,417 7,745 -8,373 -1,136 1,891 2,175
Net income 1 - - - - - - - - - 1,542 6,933 -9,432 -2,089 1,115 1,283
Net margin - - - - - - - - - 2.2% 9.62% -12.49% -2.81% 1.75% 1.75%
EPS 2 0.2100 0.4400 0.6900 0.3000 0.1600 0.4100 0.3000 0.3200 -0.0100 0.4200 1.131 -1.133 -0.0820 0.3656 0.3782
Dividend per Share 2 - - - - - - - - - - 0.5522 - - - 0.6069
Announcement Date 3/29/22 4/28/22 8/29/22 10/27/22 3/30/23 4/26/23 8/29/23 10/27/23 3/28/24 4/26/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,309 528 7,864 9,858 13,792 13,267 19,413 10,092
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.995 x 0.0568 x 0.7617 x 0.879 x 1.474 x 1.21 x 1.488 x 0.7051 x
Free Cash Flow 1 3,269 3,835 943 2,219 2,440 1,925 650 3,442
ROE (net income / shareholders' equity) 10.1% 10.3% 10.8% 9.11% 5.56% 7.22% 8.41% 8.49%
ROA (Net income/ Total Assets) 3.09% 3.14% 3.26% 3.11% 1.84% 2.2% 2.88% 2.95%
Assets 1 131,943 143,105 156,308 180,784 205,005 230,765 202,789 218,212
Book Value Per Share 2 14.70 16.00 17.40 18.10 18.50 19.50 20.60 22.10
Cash Flow per Share 2 2.120 2.410 1.780 1.280 1.410 1.930 2.010 2.170
Capex 1 2,753 3,010 4,119 2,525 2,791 3,018 3,021 3,113
Capex / Sales 1.48% 1.57% 1.91% 1.09% 1.07% 1.05% 0.95% 0.89%
Announcement Date 3/27/20 3/26/21 3/29/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Shanghai Pharmaceuticals Holding Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
17.92 CNY
Average target price
20.78 CNY
Spread / Average Target
+15.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+7.11% 8.21B
MCKESSON CORPORATION Stock McKesson Corporation
+14.53% 69.68B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.55% 7.96B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
-4.06% 7.75B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+2.26% 4.64B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.32B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.24% 4.09B
GALENICA AG Stock Galenica AG
-3.30% 3.82B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+21.42% 3.62B
MEDIPAL HOLDINGS CORPORATION Stock MediPal Holdings Corporation
+8.64% 3.39B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 601607 Stock
  4. Financials Shanghai Pharmaceuticals Holding Co., Ltd